“We have made important advancements across our clinical programs this year, and with many significant milestones in the near future, we remain focused on disciplined execution across our pipeline of transformative therapies for patients with cancer and rare diseases,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics (TARA). “We continue to make progress in our ADVANCED-2 trial of TARA-002 in non-muscle invasive bladder cancer and remain on track to report interim results from approximately 25 BCG-Unresponsive patients in the first quarter of 2026. With a favorable safety profile and its differentiated ease of administration, we believe TARA-002 has the potential to become a meaningful addition to the evolving NMIBC treatment landscape. Across our rare disease pipeline, we expect to provide an interim update from our STARBORN-1 trial in pediatric patients with lymphatic malformations and dose the first patient in our registrational THRIVE-3 trial of IV Choline Chloride in the fourth quarter of 2025.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARA:
- Protara Therapeutics, Inc. (TARA) Q3 Earnings Cheat Sheet
- Protara Therapeutics Advances Phase 2 Study for Bladder Cancer Treatment
- Protara Therapeutics’ Choline Chloride Study: A Potential Game-Changer for Intestinal Failure Treatment
- Protara Therapeutics’ TARA-002 Study: A Potential Game-Changer for Lymphatic Malformations
- Optimistic Outlook for Protara Therapeutics: Buy Rating Driven by Promising TARA-002 Developments and Strategic Opportunities